company background image
BOT logo

Botanix Pharmaceuticals ASX:BOT Stock Report

Last Price

AU$0.36

Market Cap

AU$567.0m

7D

9.1%

1Y

242.9%

Updated

23 Jun, 2024

Data

Company Financials +

Botanix Pharmaceuticals Limited

ASX:BOT Stock Report

Market Cap: AU$567.0m

BOT Stock Overview

Engages in the research and development of dermatology and antimicrobial products in Australia.

BOT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Botanix Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Botanix Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.36
52 Week HighAU$0.36
52 Week LowAU$0.10
Beta1.91
11 Month Change20.00%
3 Month Change89.47%
1 Year Change242.86%
33 Year Change361.54%
5 Year Change100.00%
Change since IPO1,100.00%

Recent News & Updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21
Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21
Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06
Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03
Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05
Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10
Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Jan 12
We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Jul 01
We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Mar 18
We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24
The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30
We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Shareholder Returns

BOTAU PharmaceuticalsAU Market
7D9.1%-2.0%0.8%
1Y242.9%64.6%10.3%

Return vs Industry: BOT exceeded the Australian Pharmaceuticals industry which returned 64.6% over the past year.

Return vs Market: BOT exceeded the Australian Market which returned 10.3% over the past year.

Price Volatility

Is BOT's price volatile compared to industry and market?
BOT volatility
BOT Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement8.3%
10% most volatile stocks in AU Market16.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: BOT's share price has been volatile over the past 3 months.

Volatility Over Time: BOT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198411Howie McKibbonwww.botanixpharma.com

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.

Botanix Pharmaceuticals Limited Fundamentals Summary

How do Botanix Pharmaceuticals's earnings and revenue compare to its market cap?
BOT fundamental statistics
Market capAU$567.05m
Earnings (TTM)-AU$10.02m
Revenue (TTM)AU$437.22k

1,297x

P/S Ratio

-56.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOT income statement (TTM)
RevenueAU$437.22k
Cost of RevenueAU$1.61m
Gross Profit-AU$1.18m
Other ExpensesAU$8.85m
Earnings-AU$10.02m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0064
Gross Margin-269.36%
Net Profit Margin-2,292.73%
Debt/Equity Ratio0%

How did BOT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.